430 related articles for article (PubMed ID: 32476270)
1. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
2. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
5. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
7. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC
Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
[TBL] [Abstract][Full Text] [Related]
8. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
Flamme I; Ellinghaus P; Urrego D; Krüger T
PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
[TBL] [Abstract][Full Text] [Related]
9. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
10. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
11. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
12. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
13. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
15. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
Kular D; Macdougall IC
Pediatr Nephrol; 2019 Mar; 34(3):365-378. PubMed ID: 29569190
[TBL] [Abstract][Full Text] [Related]
16. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
[TBL] [Abstract][Full Text] [Related]
18. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
Maruno S; Tanaka T; Nangaku M
Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
20. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study.
Eisenga MF; De Jong MA; Van der Meer P; Leaf DE; Huls G; Nolte IM; Gaillard CAJM; Bakker SJL; De Borst MH
PLoS Med; 2019 Jun; 16(6):e1002818. PubMed ID: 31170159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
